AbbVie Inc. (ABBV)

Oncology Corporate Profile

Stock Performance

60.7000
-0.2300

3 Month Stock History Chart

HQ Location

100 Abbott Park Rd.
North Chicago, IL 60064

Company Description

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.

Website: http://www.abbvie.com

Brand Generic Indication
Empliciti®elotuzumabEmpliciti® is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies
Imbruvica® ibrutinibImbruvica® is a kinase inhibitor indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
Venclexta®venetoclaxVenclexta® is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
elotuzumab (+ lenalidimide and dexamethasone) / Huluc63anti-CS1 monoclonal antibody (humanized)2nd line metastatic Multiple MyelomaIIIBristol-Myers Squibb
veliparib / ABT-888PARP inhibitorBRCA Breast cancerIII
veliparib / ABT-888PARP inhibitorNon Small Cell Lung Cancer (NSCLC)III
veliparib / ABT-888PARP inhibitorOvarian cancerIII
veliparib / ABT-888PARP inhibitorsquamous Non Small Cell Lung Cancer (NSCLC)III
veliparib / ABT-888PARP inhibitorTriple negative Breast cancerIII
Empliciti™ / elotuzumabmonoclonal antibody1st line Multiple MyelomaIII
Imbruvica® / ibrutinibBruton's tyrosine kinase (BTK) inhibitorDiffuse Large B-Cell Lymphoma (DLBCL)III
Imbruvica® / ibrutinibBruton's tyrosine kinase (BTK) inhibitorFollicular Lymphoma (FL)III
Imbruvica® / ibrutinibBruton's tyrosine kinase (BTK) inhibitorMultiple MyelomaIII
Imbruvica® / ibrutinibBruton's tyrosine kinase (BTK) inhibitorPancreatic cancerIII
Venclexta™ / ABT-199Bcl-2 inhibitor1st line Chronic Lymphocytic Leukemia (CLL)III
Venclexta™ / ABT-199Bcl-2 inhibitorAcute Myelogenous Leukemia (AML)III
Venclexta™ / ABT-199Bcl-2 inhibitorMultiple MyelomaIII
Venclexta™ / ABT-199Bcl-2 inhibitorRelapsed refractory Chronic Lymphocytic Leukemia (CLL)III
Venclexta™ (+ Rituxan®) / venetoclax (+ rituximab) / ABT-199Bcl-2 inhibitorChronic Lymphocytic Leukemia (CLL)III
Imbruvica® / ibrutinibBruton's tyrosine kinase (BTK) inhibitorAcute Myelogenous Leukemia (AML)II
Imbruvica® / ibrutinibBruton's tyrosine kinase (BTK) inhibitorVarious cancer typesII
Rova-T / rovalpituzumab tesirine (+nivolumab and ipilimumab)antibody drug conjugateSmall Cell Lung Cancer (SCLC)IIBristol-Myers Squibb
Venclexta™ / ABT-199Bcl-2 inhibitorDiffuse Large B-Cell Lymphoma (DLBCL)II
Venclexta™ / ABT-199Bcl-2 inhibitorFollicular Lymphoma (FL)II
ABBV-075small molecule Bromodomain and Extra-Terminal motif (BET) inhibitorAcute Myelogenous Leukemia (AML)I
ABBV-075small molecule Bromodomain and Extra-Terminal motif (BET) inhibitorMultiple MyelomaI
ABBV-838antibody drug conjugateMultiple MyelomaI
ABBV-075small molecule Bromodomain and Extra-Terminal motif (BET) inhibitorVarious cancer typesI
ABBV-085antibody drug conjugateVarious cancer typesI
ABBV-221antibody drug conjugateVarious cancer typesI
ABBV-339antibody drug conjugateVarious cancer typesI
ABT-165Dual variable domain immunoglobulin (DVD)Various cancer typesI
Rova-T / rovalpituzumab tesirineantibody drug conjugateNeuroendocrine tumorI

View additional information on product candidates here »

Source: http://www.abbvie.com

Recent News Headlines

8/21/2017 06:17 am

8/21/2017 06:17 am

8/21/2017 06:17 am

8/21/2017 06:17 am

8/20/2017 06:17 am

8/20/2017 06:17 am

8/20/2017 06:17 am

8/18/2017 06:17 am

8/18/2017 06:17 am

8/18/2017 06:17 am

8/17/2017 06:17 am

8/16/2017 06:17 am

8/16/2017 06:17 am

8/16/2017 06:17 am

8/16/2017 06:17 am

8/14/2017 12:17 pm

8/14/2017 12:17 pm

8/12/2017 06:17 am

8/12/2017 06:17 am

8/11/2017 06:17 am

8/11/2017 06:17 am

8/11/2017 06:17 am

8/11/2017 06:17 am

8/10/2017 06:17 pm

8/10/2017 06:17 am